Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Long-term results of national treatment trials in childhood acute lymphoblastic leukaemia in several Middle/East European countries

Long-term results of national treatment trials in childhood acute lymphoblastic leukaemia in... editorial memo (2011) Vol. 4: 140–141 DOI 10.1007/s12254-011-0276-1 Printed in Austria © Springer-Verlag 2011 Long-term results of national treatment trials in childhood acute lymphoblastic leukaemia in several Middle/East European countries Jan Starý, M.D. J. Starý 2nd Faculty of Medicine, Department of Pediatric Hematology and Oncology, Charles University and University Hospital Motol, Prague, Czech Republic Received 1 February 2011; accepted 8 March 2011 beginning of the 21st century. ALL is a highly chemosensitive disease and Introduction its successful treatment is a good indicator of the level of medical care that Acute lymphoblastic leukaemia (ALL) is the most frequent childhood children with cancer get in each country. Th ere are huge diff erences in the cancer. During the last 50 years its prognosis has improved from zero pro- outcome of this disease between developed and developing countries. bability of survival in the 1950s to more than 80% chance to be cured at the Th e international randomized multicenter trial Acute Lymphoblas- tic Leukaemia Intercontinental – BFM 2002 (ALL IC) is one of the most successful projects developed recently inside the International-BFM- Stu- Correspondence: Jan Starý, M.D., Prague, Department of Pediatric Hematology dy Group (I-BFM-SG) – one of the world-leading societies connecting http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Long-term results of national treatment trials in childhood acute lymphoblastic leukaemia in several Middle/East European countries

Loading next page...
 
/lp/springer-journals/long-term-results-of-national-treatment-trials-in-childhood-acute-0Yd20WsYKE
Publisher
Springer Journals
Copyright
Copyright © 2011 by Springer-Verlag
Subject
Medicine & Public Health; Medicine/Public Health, general; Oncology
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-011-0276-1
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2011) Vol. 4: 140–141 DOI 10.1007/s12254-011-0276-1 Printed in Austria © Springer-Verlag 2011 Long-term results of national treatment trials in childhood acute lymphoblastic leukaemia in several Middle/East European countries Jan Starý, M.D. J. Starý 2nd Faculty of Medicine, Department of Pediatric Hematology and Oncology, Charles University and University Hospital Motol, Prague, Czech Republic Received 1 February 2011; accepted 8 March 2011 beginning of the 21st century. ALL is a highly chemosensitive disease and Introduction its successful treatment is a good indicator of the level of medical care that Acute lymphoblastic leukaemia (ALL) is the most frequent childhood children with cancer get in each country. Th ere are huge diff erences in the cancer. During the last 50 years its prognosis has improved from zero pro- outcome of this disease between developed and developing countries. bability of survival in the 1950s to more than 80% chance to be cured at the Th e international randomized multicenter trial Acute Lymphoblas- tic Leukaemia Intercontinental – BFM 2002 (ALL IC) is one of the most successful projects developed recently inside the International-BFM- Stu- Correspondence: Jan Starý, M.D., Prague, Department of Pediatric Hematology dy Group (I-BFM-SG) – one of the world-leading societies connecting

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Oct 13, 2011

References